News
Video
Author(s):
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL